Helms School of Government, Liberty University, Lynchburg, Virginia.
Traffic Inj Prev. 2023;24(7):552-558. doi: 10.1080/15389588.2023.2239972. Epub 2023 Aug 3.
The present study aims to assess the effectiveness of the Drug Evaluation and Classification (DEC) program in Florida.
Data from 236 completed DEC evaluations of central nervous system (CNS) depressants, CNS stimulants, narcotic analgesics, and cannabis were analyzed using a classification process comprising toxicology findings and corresponding Drug Recognition Expert (DRE) opinions. A series of standard measures (sensitivity, specificity, false-alarm rate, miss rate, corroboration, and accuracy) were calculated to assess the effectiveness of the DEC program.
DREs provided 172 correct opinions and 23 missed opinions, resulting in an accuracy rate of 88%, sensitivity rate of 97%, specificity rate of 23%, false alarm rate of 77%, miss rate of 3%, and corroboration rate of 91%. The 12-step DRE protocol of the DEC program therefore has the desired effect of DREs formulating correct opinions. The specificity and false alarm rate were influenced by the restricted testing procedures in the state of Florida. In general, law enforcement officers certified in the DEC program with specialized training can identify drugged drivers and the correct drug category of the drug causing impairment at the time of operating a vehicle. The DEC program goals are met through rigorous training and a curriculum establishing the 12-step DRE protocol.
DRE drug classification opinions identify drugged drivers. The limitations of Florida's biological sample testing procedures have an impact on the specificity of DRE opinions. Addressing these limitations could increase the confirmation rates of the presence of drugs in the individual's biological samples, which would directly impact the conviction rates in DUI-related criminal cases. Further Florida's testing procedures need to be further studied and updated to improve the DEC program in Florida.
本研究旨在评估佛罗里达州药物评估和分类(DEC)计划的有效性。
使用分类过程分析了 236 例中枢神经系统(CNS)抑制剂、CNS 兴奋剂、阿片类镇痛药和大麻的 DEC 评估数据,该分类过程包括毒理学发现和相应的药物识别专家(DRE)意见。计算了一系列标准措施(灵敏度、特异性、误报率、漏报率、证实率和准确率),以评估 DEC 计划的有效性。
DRE 提供了 172 个正确意见和 23 个遗漏意见,准确率为 88%,灵敏度为 97%,特异性为 23%,误报率为 77%,漏报率为 3%,证实率为 91%。因此,DEC 计划的 12 步 DRE 方案具有 DRE 制定正确意见的预期效果。特异性和误报率受到佛罗里达州限制检测程序的影响。一般来说,经过 DEC 计划专门培训并获得认证的执法人员能够识别吸毒驾驶员和导致驾驶时受损的药物的正确药物类别。通过严格的培训和建立 12 步 DRE 方案的课程,实现了 DEC 计划的目标。
DRE 药物分类意见可识别吸毒驾驶员。佛罗里达州生物样本检测程序的局限性对 DRE 意见的特异性有影响。解决这些局限性可以提高个体生物样本中药物存在的确认率,这将直接影响 DUI 相关刑事案件的定罪率。此外,需要进一步研究和更新佛罗里达州的测试程序,以改进 DEC 计划。